Table 1.
Patient demographics by stress type.
| Patient characteristic | Regadenoson (N = 209) N (%) | Adenosine (N = 187) N (%) | P-value |
|---|---|---|---|
| Age (mean ± st. dev.) | 72.3 yrs (±12.1) | 71.1 yrs (±12.7) | Ns |
| Caucasian | 206 (99.5%) | 180 (96.3%) | Ns |
| Sex (female) | 133 (63.6%) | 119 (63.6%) | Ns |
| Prior stress test (yes) | 160 (76.6%) | 133 (71.5%) | Ns |
| History of myocardial infarction | 39 (18.7%) | 24 (12.9%) | Ns |
| Coronary artery bypass grafting | 48 (23.0%) | 39 (21.0%) | Ns |
| Prior catheterization/PCI | 98 (46.9%) | 74 (40.0%) | Ns |
| Chronic obstructive pulmonary disease | 37 (17.7%) | 21 (11.3%) | 0.07 |
| Asthma | 23 (11.0%) | 13 (7.0%) | Ns |
| Hypertension | 141 (67.5%) | 118 (63.8%) | Ns |
| Cerebrovascular accident | 26 (12.4%) | 33 (17.7%) | Ns |
| Diabetes mellitus | 67 (32.1%) | 57 (30.7%) | Ns |
| Hyperlipidemia | 117 (56.5%) | 94 (50.8%) | Ns |
| Current tobacco abuse | 28 (13.4%) | 19 (10.2%) | Ns |
| Aspirin | 112 (53.9%) | 94 (50.5%) | Ns |
| Plavix | 35 (16.8%) | 30 (16.1%) | Ns |
| Beta-blockers | 89 (42.8%) | 63 (33.9%) | 0.07 |
| Nitrates | 19 (9.1%) | 10 (5.4%) | Ns |
| Calcium channel blockers | 42 (20.2%) | 16 (8.6%) | 0.001 |
| Lipid lowering therapy-statin | 90 (43.5%) | 62 (33.3%) | 0.04 |
| Lipid lowering therapy-nonstatin | 18 (8.7%) | 10 (5.4%) | Ns |
Ns = Not Significant.